Applications of Biological Therapy for Latent Infections: Benefits and Risks.
biological therapy
latent infection
pathogen reactivation
risk management
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
24 Aug 2024
24 Aug 2024
Historique:
received:
18
07
2024
revised:
20
08
2024
accepted:
22
08
2024
medline:
14
9
2024
pubmed:
14
9
2024
entrez:
14
9
2024
Statut:
epublish
Résumé
Biological therapies have revolutionized medical treatment by targeting the key mediators or receptors involved in inflammatory responses, thereby effectively suppressing inflammation and achieving beneficial outcomes. They are more advanced than conventional therapies using corticosteroids and immunosuppressants, offering effective solutions for autoimmune diseases, cancer, transplant rejection, and various infectious diseases, including coronavirus disease 2019. Although they exert low immunosuppressive effects, biological therapies can reactivate specific biological targets associated with infections. This review summarizes the currently available biological therapies and discusses their immunosuppressive mechanisms and clinical applications, highlighting the variations in the types and frequencies of infection recurrence induced by different biological agents. Additionally, this review describes the risk factors associated with various biological agents, thus aiding clinicians in selecting the most appropriate biological therapy.
Identifiants
pubmed: 39273134
pii: ijms25179184
doi: 10.3390/ijms25179184
pii:
doi:
Substances chimiques
Immunosuppressive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : JSPS KAKENHI
ID : JP 20K09824
Organisme : Ministry of Health, Labor, and Welfare of Japan
ID : 22FC0201
Organisme : Japan Agency for Medical Research and Development, AMED
ID : 23fk0108671h0001, 23fk0108672h0001
Organisme : Takeda Science Foundation
ID : FY2023